BioSpace News Archive

The American College of Rheumatology and the Association for Rheumatology Professionals welcomes members of the press to write about research presented at the 2019 ACR/ARP Annual Meeting.

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced an update on its clinical pipeline and financial results for the fiscal second quarter ended April 30, 2019.

Veracyte, Inc. (Nasdaq: VCYT) announced today that findings from a new real-world study show that the company’s Afirma® Genomic Sequencing Classifier (GSC) helps to identify significantly more benign thyroid nodules and further reduce unnecessary surgeries in thyroid cancer diagnosis, as compared to the original Afirma test

TPC Wire & Cable Corp. (TPC), a portfolio company of Audax Private Equity, announced today that it has completed the acquisition of EZ Form Cable Corporation, an AS9100D Certified provider of coaxial cable based in Hamden, Connecticut. EZ Form is a leading provider of RF & microwave interconnect products for specialized applications common in defense, space, wireless communications and medical instrumentation.

The cause of and cure for Alzheimer’s disease remain frustratingly elusive. In an effort to change that, the Infectious Diseases Society of America (IDSA) Foundation, with generous support from Alzheimer’s Germ Quest, Inc. and The Benter Foundation is offering five, one-time $100,000 grants to researchers seeking to identify a potential infectious link to the disease.

Wolf & Company P.C. is pleased to announce that Renee Broadbent has joined the firm, working with clients in the healthcare industry on improving their information security practices and compliance

Varian (NYSE: VAR) today announced it has acquired Austin, Texas-based Endocare and Hangzhou, China-based, Alicon, to expand its portfolio of multidisciplinary integrated cancer care solutions.

In a predefined sub-analysis of the BRIGHT head-to-head study evaluating Toujeo® (insulin glargine injection) 300 Units/mL with Tresiba® (insulin degludec), Toujeo resulted in greater improvement in blood sugar control (HbA1c) compared to Tresiba (-1.72% vs. -1.30%, respectively) with no difference in incidence or event rates of confirmed low blood sugar (hypoglycemia) in adults with type 2 diabetes and moderately to severely impaired renal function (eGFR <60 mL/min/1.73 m2).

etectRx™ Inc., an early-stage digital health company, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,292,642 for an “Electronic Medication Compliance Monitoring System and Associated Methods.”

Oncoceutics, Inc. announced a publication in the Journal for ImmunoTherapy of Cancer demonstrating ONC201 immunostimulatory activity in advanced cancer patients when given the recommended phase II dose (RP2D) of 625 mg orally every one week.